1. Volume 356, Issue 9239, Pages 1384-1391 (October 2000)
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow- supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial 
Prof Jonas Bergh, MD, Tom Wiklund, MD, Björn Erikstein, MD, Elisabet Lidbrink, MD, Henrik Lindman, MD, Per Malmström, MD, Pirkko Kellokumpu-Lehtinen, MD, Nils-Olof Bengtsson, MD, Gustaf Söderlund, MD, Gun Anker, MD, Erik Wist, MD, Susanne Ottosson, MD, Eeva Salminen, MD, Per Ljungman, MD, Harald Holte, MD, Jonas Nilsson, BSc, Prof Carl Blomqvist, MD, Nils Wilking, MD 
The Lancet 
Volume 356, Issue 9239, Pages (October 2000)
DOI: /S (00)
Copyright © 2000 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (00) )
Copyright © 2000 Elsevier Ltd Terms and Conditions

3. Figure 2
Kaplan-Meier plot of relapse-free survival for tailored FEC versus CTCb
p=0·013 (log-rank test), p=0·044 (double triangular test).
The Lancet  , DOI: ( /S (00) )
Copyright © 2000 Elsevier Ltd Terms and Conditions

4. Figure 3
Kaplan-Meier plot of relapse-free survival for tailored FEC in relation to given doses
The Lancet  , DOI: ( /S (00) )
Copyright © 2000 Elsevier Ltd Terms and Conditions

5. Figure 4
Kaplan-Meier plot of overall survival for tailored FEC versus CTCb
p=0·012 (log-rank test).
The Lancet  , DOI: ( /S (00) )
Copyright © 2000 Elsevier Ltd Terms and Conditions